Rheumatoid Arthritis Drugs Market 2024-2028

The rheumatoid arthritis drugs market is forecasted to grow by USD 16045.12 mn during 2023-2028, accelerating at a CAGR of 7.5% during the forecast period. The report on the rheumatoid arthritis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising cases of RA and focus on increasing number of rheumatologists, availability of improved diagnostic modalities, and need for affordable biologics for RA.

The rheumatoid arthritis drugs market is segmented as below:

By Drug Class

Disease-modifying anti-rheumatic drugs
Nonsteroidal anti-inflammatory drugs
Corticosteroids

By Type

Biologics
Small Molecules

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the health plan offerings for RA as one of the prime reasons driving the rheumatoid arthritis drugs market growth during the next few years. Also, use of biologics/biosimilars for treatment of RA and use of gene therapy for RA treatment will lead to sizable demand in the market.

The report on the rheumatoid arthritis drugs market covers the following areas:

Rheumatoid arthritis drugs market sizing
Rheumatoid arthritis drugs market forecast
Rheumatoid arthritis drugs market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rheumatoid arthritis drugs market vendors that include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor Biopharma Holdings Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA. Also, the rheumatoid arthritis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global rheumatoid arthritis drugs market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global rheumatoid arthritis drugs market 2018 - 2022 ($ million)
4.2 Drug Class Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
4.3 Type Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

6.1 Market segments
Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
6.2 Comparison by Drug Class
Exhibit 32: Chart on Comparison by Drug Class
Exhibit 33: Data Table on Comparison by Drug Class
6.3 Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028
Exhibit 34: Chart on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
6.4 Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028
Exhibit 38: Chart on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
6.5 Corticosteroids - Market size and forecast 2023-2028
Exhibit 42: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibit 43: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibit 44: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Drug Class
Exhibit 46: Market opportunity by Drug Class ($ million)
Exhibit 47: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Type

7.1 Market segments
Exhibit 48: Chart on Type - Market share 2023-2028 (%)
Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
7.2 Comparison by Type
Exhibit 50: Chart on Comparison by Type
Exhibit 51: Data Table on Comparison by Type
7.3 Biologics - Market size and forecast 2023-2028
Exhibit 52: Chart on Biologics - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Biologics - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Biologics - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Biologics - Year-over-year growth 2023-2028 (%)
7.4 Small Molecules - Market size and forecast 2023-2028
Exhibit 56: Chart on Small Molecules - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Small Molecules - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Small Molecules - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Small Molecules - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Type
Exhibit 60: Market opportunity by Type ($ million)
Exhibit 61: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 UK - Market size and forecast 2023-2028
Exhibit 87: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.9 China - Market size and forecast 2023-2028
Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
9.10 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.11 France - Market size and forecast 2023-2028
Exhibit 99: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on France - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 111: AbbVie Inc. - Overview
Exhibit 112: AbbVie Inc. - Product/Service
Exhibit 113: AbbVie Inc. - Key news
Exhibit 114: AbbVie Inc. - Key offerings
12.4 Amgen Inc.
Exhibit 115: Amgen Inc. - Overview
Exhibit 116: Amgen Inc. - Product/Service
Exhibit 117: Amgen Inc. - Key offerings
12.5 Bristol Myers Squibb Co.
Exhibit 118: Bristol Myers Squibb Co. - Overview
Exhibit 119: Bristol Myers Squibb Co. - Product/Service
Exhibit 120: Bristol Myers Squibb Co. - Key news
Exhibit 121: Bristol Myers Squibb Co. - Key offerings
12.6 Eli Lilly and Co.
Exhibit 122: Eli Lilly and Co. - Overview
Exhibit 123: Eli Lilly and Co. - Product/Service
Exhibit 124: Eli Lilly and Co. - Key news
Exhibit 125: Eli Lilly and Co. - Key offerings
12.7 F. Hoffmann La Roche Ltd.
Exhibit 126: F. Hoffmann La Roche Ltd. - Overview
Exhibit 127: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 128: F. Hoffmann La Roche Ltd. - Key news
Exhibit 129: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 130: F. Hoffmann La Roche Ltd. - Segment focus
12.8 Genor Biopharma Holdings Ltd.
Exhibit 131: Genor Biopharma Holdings Ltd. - Overview
Exhibit 132: Genor Biopharma Holdings Ltd. - Product/Service
Exhibit 133: Genor Biopharma Holdings Ltd. - Key offerings
12.9 Gilead Sciences Inc.
Exhibit 134: Gilead Sciences Inc. - Overview
Exhibit 135: Gilead Sciences Inc. - Product/Service
Exhibit 136: Gilead Sciences Inc. - Key news
Exhibit 137: Gilead Sciences Inc. - Key offerings
12.10 Johnson and Johnson
Exhibit 138: Johnson and Johnson - Overview
Exhibit 139: Johnson and Johnson - Business segments
Exhibit 140: Johnson and Johnson - Key news
Exhibit 141: Johnson and Johnson - Key offerings
Exhibit 142: Johnson and Johnson - Segment focus
12.11 Kangstem Biotech Co. Ltd.
Exhibit 143: Kangstem Biotech Co. Ltd. - Overview
Exhibit 144: Kangstem Biotech Co. Ltd. - Product/Service
Exhibit 145: Kangstem Biotech Co. Ltd. - Key offerings
12.12 Novartis AG
Exhibit 146: Novartis AG - Overview
Exhibit 147: Novartis AG - Business segments
Exhibit 148: Novartis AG - Key offerings
Exhibit 149: Novartis AG - Segment focus
12.13 Oryn Therapeutics
Exhibit 150: Oryn Therapeutics - Overview
Exhibit 151: Oryn Therapeutics - Product/Service
Exhibit 152: Oryn Therapeutics - Key offerings
12.14 Pfizer Inc.
Exhibit 153: Pfizer Inc. - Overview
Exhibit 154: Pfizer Inc. - Product/Service
Exhibit 155: Pfizer Inc. - Key news
Exhibit 156: Pfizer Inc. - Key offerings
12.15 Sanofi
Exhibit 157: Sanofi - Overview
Exhibit 158: Sanofi - Business segments
Exhibit 159: Sanofi - Key news
Exhibit 160: Sanofi - Key offerings
Exhibit 161: Sanofi - Segment focus
12.16 Sorrento Therapeutics Inc.
Exhibit 162: Sorrento Therapeutics Inc. - Overview
Exhibit 163: Sorrento Therapeutics Inc. - Business segments
Exhibit 164: Sorrento Therapeutics Inc. - Key offerings
Exhibit 165: Sorrento Therapeutics Inc. - Segment focus
12.17 UCB SA
Exhibit 166: UCB SA - Overview
Exhibit 167: UCB SA - Product/Service
Exhibit 168: UCB SA - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 169: Inclusions checklist
Exhibit 170: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 171: Currency conversion rates for US$
13.4 Research methodology
Exhibit 172: Research methodology
Exhibit 173: Validation techniques employed for market sizing
Exhibit 174: Information sources
13.5 List of abbreviations
Exhibit 175: List of abbreviations

List of Exhibits

Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 6: Executive Summary - Chart on Market Segmentation by Type
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global rheumatoid arthritis drugs market 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Type Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits 31: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Drug Class
Exhibits 33: Data Table on Comparison by Drug Class
Exhibits 34: Chart on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Data Table on Disease-modifying anti-rheumatic drugs - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Chart on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Disease-modifying anti-rheumatic drugs - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Data Table on Nonsteroidal anti-inflammatory drugs - Market size and forecast 2023-2028 ($ million)
Exhibits 40: Chart on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Nonsteroidal anti-inflammatory drugs - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits 43: Data Table on Corticosteroids - Market size and forecast 2023-2028 ($ million)
Exhibits 44: Chart on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Corticosteroids - Year-over-year growth 2023-2028 (%)
Exhibits 46: Market opportunity by Drug Class ($ million)
Exhibits 47: Data Table on Market opportunity by Drug Class ($ million)
Exhibits 48: Chart on Type - Market share 2023-2028 (%)
Exhibits 49: Data Table on Type - Market share 2023-2028 (%)
Exhibits 50: Chart on Comparison by Type
Exhibits 51: Data Table on Comparison by Type
Exhibits 52: Chart on Biologics - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Data Table on Biologics - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Chart on Biologics - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Biologics - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Small Molecules - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Data Table on Small Molecules - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Chart on Small Molecules - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Small Molecules - Year-over-year growth 2023-2028 (%)
Exhibits 60: Market opportunity by Type ($ million)
Exhibits 61: Data Table on Market opportunity by Type ($ million)
Exhibits 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 65: Chart on Geographic comparison
Exhibits 66: Data Table on Geographic comparison
Exhibits 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 89: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 92: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 93: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on France - Market size and forecast 2023-2028 ($ million)
Exhibits 100: Data Table on France - Market size and forecast 2023-2028 ($ million)
Exhibits 101: Chart on France - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on France - Year-over-year growth 2023-2028 (%)
Exhibits 103: Market opportunity By Geographical Landscape ($ million)
Exhibits 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 105: Impact of drivers and challenges in 2023 and 2028
Exhibits 106: Overview on Criticality of inputs and Factors of differentiation
Exhibits 107: Overview on factors of disruption
Exhibits 108: Impact of key risks on business
Exhibits 109: Vendors covered
Exhibits 110: Matrix on vendor position and classification
Exhibits 111: AbbVie Inc. - Overview
Exhibits 112: AbbVie Inc. - Product/Service
Exhibits 113: AbbVie Inc. - Key news
Exhibits 114: AbbVie Inc. - Key offerings
Exhibits 115: Amgen Inc. - Overview
Exhibits 116: Amgen Inc. - Product/Service
Exhibits 117: Amgen Inc. - Key offerings
Exhibits 118: Bristol Myers Squibb Co. - Overview
Exhibits 119: Bristol Myers Squibb Co. - Product/Service
Exhibits 120: Bristol Myers Squibb Co. - Key news
Exhibits 121: Bristol Myers Squibb Co. - Key offerings
Exhibits 122: Eli Lilly and Co. - Overview
Exhibits 123: Eli Lilly and Co. - Product/Service
Exhibits 124: Eli Lilly and Co. - Key news
Exhibits 125: Eli Lilly and Co. - Key offerings
Exhibits 126: F. Hoffmann La Roche Ltd. - Overview
Exhibits 127: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 128: F. Hoffmann La Roche Ltd. - Key news
Exhibits 129: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 130: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 131: Genor Biopharma Holdings Ltd. - Overview
Exhibits 132: Genor Biopharma Holdings Ltd. - Product/Service
Exhibits 133: Genor Biopharma Holdings Ltd. - Key offerings
Exhibits 134: Gilead Sciences Inc. - Overview
Exhibits 135: Gilead Sciences Inc. - Product/Service
Exhibits 136: Gilead Sciences Inc. - Key news
Exhibits 137: Gilead Sciences Inc. - Key offerings
Exhibits 138: Johnson and Johnson - Overview
Exhibits 139: Johnson and Johnson - Business segments
Exhibits 140: Johnson and Johnson - Key news
Exhibits 141: Johnson and Johnson - Key offerings
Exhibits 142: Johnson and Johnson - Segment focus
Exhibits 143: Kangstem Biotech Co. Ltd. - Overview
Exhibits 144: Kangstem Biotech Co. Ltd. - Product/Service
Exhibits 145: Kangstem Biotech Co. Ltd. - Key offerings
Exhibits 146: Novartis AG - Overview
Exhibits 147: Novartis AG - Business segments
Exhibits 148: Novartis AG - Key offerings
Exhibits 149: Novartis AG - Segment focus
Exhibits 150: Oryn Therapeutics - Overview
Exhibits 151: Oryn Therapeutics - Product/Service
Exhibits 152: Oryn Therapeutics - Key offerings
Exhibits 153: Pfizer Inc. - Overview
Exhibits 154: Pfizer Inc. - Product/Service
Exhibits 155: Pfizer Inc. - Key news
Exhibits 156: Pfizer Inc. - Key offerings
Exhibits 157: Sanofi - Overview
Exhibits 158: Sanofi - Business segments
Exhibits 159: Sanofi - Key news
Exhibits 160: Sanofi - Key offerings
Exhibits 161: Sanofi - Segment focus
Exhibits 162: Sorrento Therapeutics Inc. - Overview
Exhibits 163: Sorrento Therapeutics Inc. - Business segments
Exhibits 164: Sorrento Therapeutics Inc. - Key offerings
Exhibits 165: Sorrento Therapeutics Inc. - Segment focus
Exhibits 166: UCB SA - Overview
Exhibits 167: UCB SA - Product/Service
Exhibits 168: UCB SA - Key offerings
Exhibits 169: Inclusions checklist
Exhibits 170: Exclusions checklist
Exhibits 171: Currency conversion rates for US$
Exhibits 172: Research methodology
Exhibits 173: Validation techniques employed for market sizing
Exhibits 174: Information sources
Exhibits 175: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global rheumatoid arthritis drugs market: AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor Biopharma Holdings Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is health plan offerings for RA.'

According to the report, one of the major drivers for this market is the rising cases of RA and focus on increasing number of rheumatologists.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.
Bristol Myers Squibb Co.
Eli Lilly and Co.
F. Hoffmann La Roche Ltd.
Galmed Pharmaceuticals Ltd.
Genor Biopharma Holdings Ltd.
Gilde Healthcare
Gilead Sciences Inc.
GlaxoSmithKline Plc
Johnson and Johnson
Kangstem Biotech Co. Ltd.
Novartis AG
Oryn Therapeutics
Pfizer Inc.
Sanofi
Sorrento Therapeutics Inc.
Taisho Pharmaceutical Holdings Co. Ltd.
UCB SA

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€2205EUR$2,500USD£1,902GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€3528EUR$4,000USD£3,043GBP

The rheumatoid arthritis drugs market is segmented as below:

By Drug Class

By Type

By Geographical Landscape

The report on the rheumatoid arthritis drugs market covers the following areas:

Table of Contents

Executive Summary

Companies Mentioned (Partial List)

Related Topics

Related Reports

Rheumatoid Arthritis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Rheumatoid Arthritis Therapeutics - Global Strategic Business Report

Rheumatoid Arthritis Market - A Global and Regional Analysis: Focus on Drug Type, Country, and Region - Analysis and Forecast, 2025-2035

Rheumatoid Arthritis Drugs Market Report 2025

TNF Inhibitors for the Treatment of Rheumatoid Arthritis Market by Product, Route Of Administration, Therapy Regimen, Treatment Line, Distribution Channel, Patient Age Group, Patient Gender - Global Forecast to 2030